• > NICE Guidance
Investors in People
Home  > Chief Medical Officer Public Health and R&D  > Safety, Quality and Standards  > Guidance  > NICE Guidance 

Safety, Quality and Standards

NICE (The National Institute for Health and Clinical Excellence)

NICE is a Special Health Authority tasked with providing guidance on current best practice in health treatment and care, including public health, to the NHS in England and Wales.  The Department has a formal link with the Institute under which all NICE guidance, published from 1 July 2006, is reviewed locally for its applicability to Northern Ireland and, where found to be applicable, is endorsed by the Department for implementation in the HSC.  Further details are available in the circulars below.

NICE Guidance

NICE Guidance endorsed to date is set out below:
  • National Institute for Health and Clinical Excellence (NICE) Clinical Guideline No 84 Diarrhoea and Vomiting Due to Gastroenteritis in Children Under 5
  • National Institute for Health and Clinical Excellence (NICE) Technology Appraisal No 172 - Head and Neck Cancer (squamous cell carcinoma) cetuximab
  • National Institute for Health and Clinical Excellence (NICE) Technology Appraisal No 170 Rivaroxaban for the Prevention of Venous Thromboembolism after Total Hip or Total Knee Replacement in Adults
  • National Institute for Health and Clinical Excellence (NICE) Technology Appraisal No 167 Endovascular Stent Grafts for the Treatment of Abdominal Aortic Aneurysms
  • National Institute for Health and Clinical Excellence (NICE) Technology Appraisal No 164 Febuxostat for the Treatment of Hyperuricaemia in People with Gout
  • National Institute for Health and Clinical Excellence (NICE) Clinical Guideline No 75 - Metastatic Spinal Cord Compression: Diagnosis and Management of Adults at risk of and with Metastatic Spinal Cord Compression
  • National Institute for Health and Clinical Excellence (NICE) Technology Appraisal No 168 Amantadine, Oseltamivir and Zanamivir for the Treatment of Influenza (review of CG 58)
  • National Institute for Health and Clinical Excellence (NICE) Technology Appraisal No 165 Machine Perfusion Systems and Cold Static Storage of Kidneys from Deceased Donors
  • National Institute for Health and Clinical Excellence (NICE) Technology Appraisal No 163 Infliximab for Acute Exacerbations of Ulcerative Colitis
  • National Institute for Health and Clinical Excellence (NICE) Technology Appraisal No 158 – Amantadine, Oseltamivir and Zanamivir for Influenza Prophylaxis
  • National Institute for Health and Clinical Excellence (NICE) Technology Appraisal No 154 – Telbivudine for the Treatment of Chronic Hepatitis B
  • National Institute for Health and Clinical Excellence (NICE) Technology Appraisal No 153 – Entecavir for the Treatment of Chronic Hepatitis B
  • National Institute for Health and Clinical Excellence (NICE) Cancer Services No CSGSTIM – Improving Outcomes for People with Skin Tumours Including Melanoma
  • National Institute for Health and Clinical Excellence (NICE) Technology Appraisal No161Osteoporosis – Secondary Prevention Including Strontium Ranelate
  • National Institute for Health and Clinical Excellence (NICE) Interventional Procedure Programme Guideline No 302 Percutaneous Laser Revascularisation for Refactory Angina Pectoris
  • National Institute for Health and Clinical Excellence (NICE) Interventional Procedure Programme Guideline No 301 – Transmyocardial Laser Revascularisation for Refractory Angina Pectoris
  • National Institute for Health and Clinical Excellence (NICE) This revised circular supersedes circular HSC (SQSD) (NICE) 11/07 NICE Technology Appraisal Guidance No TA103 - Psoriasis - Efalizumab and Etanercept
  • National Institute for Health and Clinical Excellence (NICE) Technology Appraisal No162 Erlotinib for the Treatment of Non-small Cell Lung Cancer
  • National Institute for Health and Clinical Excellence (NICE) Technology Appraisal No159 Spinal Cord Stimulation for Chronic Pain of Neuropathic of Ischaemic Origin
  • National Institute for Health and Clinical Excellence (NICE) Clinical Guideline No67 Lipid Modification Cardiovascular risk asssessment and the modification of blood lipids for the primary and secondary prevention of cardiovascular disease
  • National Institute for Health and Clinical Excellence (NICE) Clinical Guideline No66 Type 2 diabetes - the management of type 2 diabetes (update)
  • National Institute for Health and Clinical Excellence (NICE) Clinical Guideline No65 Management of inadvertent perioperative hypothermia in adults
  • National Institute for Health and Clinical Excellence (NICE) Technology Appraisal No143  Adalimumab, etanercept and infliximab for ankylosing spondylitis
  • National Institute for Health and Clinical Excellence (NICE) Technology Appraisal No 142 Erythropoietin (alpha and beta) and darbepoetin for the treatment of cancer -treatment induced anaemia
  • National Institute for Health and Clinical Excellence (NICE) Technology Appraisal No138 Corticosteroids for the treatment of chronic asthma in adults and children aged 12 years and over
  • National Institute for Health and Clinical Excellence (NICE) Clinical Guideline No63 Diabetes in Pregnancy : management of  diabetes and its complications from pre-conception to postnatal period
  • National Institute for Health and Clinical Excellence (NICE) Clinical Guideline No61- Irritable Bowel Syndrome in adults: diagnosis and management of irritable bowel syndrome in primary care
  • National Institute for Health and Clinical Excellence (NICE) Clinical Guideline No60 - Surgical Management of  Children with Otitis Media Effusion
  • National Institute for Health and Clinical Excellence (NICE) Technology Appraisal No 141 - Abatacept for the Treatment of Rheumatoid Arthritis
  • National Institute for Health and Clinical Excellence (NICE) Technology Appraisal No 140 - Infliximab for the treatment of Ulcerative Colitis
  • National Institute for Health and Clinical Excellence (NICE)Technology Appraisal No 139 – Continuous Positive Airway Pressure (CPAP) for the Treatment of Obstructive Sleep Apnoea/Hypopnoea Syndrome (OSAHS)
  • National Institute for Health and Clinical Excellence (NICE) NICE Technology Appraisal No137 – Rituximab for the Treatment of Relapsed or Refractory Stage iii or Stage iv Follicular Non-Hodgkin’s Lymphoma
  • National Institute for Health and Clinical Excellence (NICE) NICE Technology Appraisal No 156 - Pregnancy - Routine Antenatal Anti-D Prophylaxis for Women who are Rhesus D Negative
  • National Institute for Health and Clinical Excellence (NICE) NICE Technology Appraisal No 155 - Pegaptanib and Ranibizumab for Age-related Macular Degeneration
  • National Institute for Health and Clinical Excellence (NICE) NICE Clinical Guideline No 64 - Antibiotic Prophylaxis Against Infective Endocarditis
  • National Institute for Health and Clinical Excellence (NICE) Technology Appraisal TA 131 Inhaled Corticosteroids for the treatment of chronic Asthma in Children Under the Age of 12 Years
  • National Institute for Health and Clinical Excellence (NICE) Technology Appraisal TA 130 Adalimumab, Etanercept and Infliximab for the treatment of Rheumatoid Arthritis
  • National Institute for Health and Clinical Excellence (NICE) Technology Appraisal 128 - Stapled Haemorroidopexy for the treatment of Haemorrhoids
  • National Institute for Health and Clinical Excellence (NICE) Technology Appraisal No TA 102 Parent-Training/Education Programmes in the management of Children with conduct Disorders
  • National Institute for Health and Clinical Excellence (NICE) Technology Appraisal No TA 135 - Pemetrexed Disodium for the Treatment of Malignant Pleural Mesothelioma
  • National Institute for Health and Clinical Excellence (NICE) Technology Appraisal No TA 122 - Alteplase for the Treatment of Acute Ischaemic Stroke
  • National Institute for Health and Clinical Excellence (NICE) Technology Appraisal No TA 117 - Cinacalcet for the Treatment Secondary Hyperparathyroidism in Patients with End-Stage Renal Disease on Maintenance Dialysis
  • National Institute for Health and Clinical Excellence (NICE) Technology Appraisal No TA 119 - Fludarabine Monotherapy for the First-line Treatment of Chronic Lymphocytic Leukaemia (CLL)
  • National Institute for Health and Clinical Excellence (NICE) Technology Appraisal No TA 106 - Peginterferon alfa and ribavirin for the treatment of mild chronic hepatitis C
  • National Institute for Health and Clinical Excellence (NICE) No CG 38 - Bipolar Disorder - The Management of bipolar disorder in adults, children and adolescents, in Primary and Secondary care.
  • National Institute for Health and Clinical Excellence (NICE) No CG 35 - Parkinson's Disease - Diagnosis and Management in Primary and Secondary Care
  • National Institute for Health and Clinical Excellence (NICE) Technology Appraisal for Implementation in the HSC - Colorectal Cancer - Bevacizumab and Cetuximab
  • National Institute for Health and Clinical Excellence (NICE) Technology Appraisal for Implementation in the HSC - Drug Misuse - Methadone and Buprenorphine
  • National Institute for Health and Clinical Excellence (NICE) Technology Appraisal for Implementation in the HSC - Inhaled Insulin for the Treatment of Diabetes Mellitus Types 1 & 2
  • National Institute for Health and Clinical Excellence (NICE) Technology Appraisal for Implementation in the HPSS - Prostate Cancer (Hormone Refractory) Docetaxal
  • National Institute for Health and Clinical Excellence (NICE) Technology Appraisal for Implementation in the HPSS - Colorectal Cancer - Laparoscopic Surgery
  • National Institute for Health and Clinical Excellence (NICE) Technology Appraisal for Implementation in the HPSS - Breast Cancer (early) Trastuzumab (Herceptin)
  • National Institute for Health and Clinical Excellence (NICE) Technology Appraisal for Implementation in the HPSS - Psoriatic Arthritis - Etanercept & Infliximab
Quick Links
Download Free Adobe Acrobat Reader - Links to an External Site